Medical University of South Carolina - Cancer Center Support Grant

描述（由申请人提供）：南卡罗来纳医科大学（MUSC）的霍林斯癌症中心（HCC）通过P30癌症中心支持资助机制寻求国家癌症研究所（NCI）的指定，以支持其减轻南卡罗来纳及其他地区癌症负担的使命。作为南卡罗来纳州领先的学术医疗中心，在过去的十年中，MUSC一直致力于建立临床、基础、转化和基于人群的研究项目，以解决该州显著的癌症发病率和死亡率。通过NCI P20计划拨款（2001-2007）的支持，HCC已经招募并组织了97名癌症科学家，代表6个MUSC学院-医学，药学，牙科医学，护理，卫生专业和研究生学习-进行富有成效和合作的癌症研究项目。这些项目包括：癌症中的脂质信号、癌症基因与分子调控、癌症发育治疗和癌症免疫学。癌症预防和控制项目正在开发中。HCC已经扩大并将继续扩大其研究设施和资源，以促进进一步的发展。2006年，HCC在其原有的85,761英尺的建筑附近完成了一座七层塔楼，增加了超过116,000平方英尺的研究，临床和行政空间，MUSC已经承诺在2008年夏季开始建设的两座新建筑中为HCC提供额外的62,000平方英尺的研究空间。作为本次P30申请的一部分，将展示五个共享的研究资源：脂质组学、流式细胞术和细胞分选、细胞和分子成像、生物统计学和临床试验。自2004年以来，HCC已投入160万美元用于加强这五项基本和关键资源。鉴于项目研究的快速和持续发展，HCC还投资了另外600万美元，用于启动开发和优化其他七种共享资源的功能，这些资源将对HCC当前和未来的基于项目的研究计划产生重大影响。自2003年以来，这些投资使HCC的校外研究资金基础翻了一番，目前为3120万美元，NCI的资金为1210万美元。治疗性临床试验的应计费用在同一时期翻了两番。这一应用表明，HCC科学家在理解癌症生物学和开发预防、诊断和治疗癌症的新方法方面做出了重大贡献。

DESCRIPTION (provided by applicant): The Hollings Cancer Center (HCC) at the Medical University of South Carolina (MUSC) seeks National Cancer Institute (NCI) designation via the P30 Cancer Center Support Grant mechanism to support its mission to reduce the cancer burden in South Carolina and beyond. As South Carolina's leading academic medical center, MUSC has been charged and supported over the past decade to build clinical, basic, translational and population-based research programs that address the state's significant cancer morbidity and mortality. Through the support of an NCI P20 Planning Grant (2001-2007), the HCC has recruited and organized 97 cancer scientists, representing six MUSC Colleges - Medicine, Pharmacy, Dental Medicine, Nursing, Health Professions and Graduate Studies - into productive and collaborative cancer research programs. These programs are: Lipid Signaling in Cancer, Cancer Genes & Molecular Regulation, Developmental Cancer Therapeutics and Cancer Immunology. A Cancer Prevention & Control program is in development. The HCC has expanded and continues to expand its research facilities and resources to enhance further growth. In 2006, the HCC completed a seven story tower adjacent to its original 85,761 ft[2] building adding more than 116,000 ft2 in research, clinical and administrative space, and MUSC has committed an additional 62,000 ft2 of research space to the HCC in two new buildings starting construction in summer 2008. As part of this P30 application, five shared research resources will be presented: Lipidomics, Flow Cytometry & Cell Sorting, Cell & Molecular Imaging, Biostatistics and Clinical Trials. The HCC has invested $1.6 million since 2004 into enhancing these five essential and critical resources. Given the rapid and ongoing development of research in the programs, the HCC has also invested another $6 million in initiating the development and optimizing the function of seven other shared resources that will greatly impact on HCC's current and future programmatic-based research initiatives. These investments have resulted in a doubling of the HCC's extramural research funding base since 2003, currently $31.2 million with NCI funding representing $12.1million. Accrual to therapeutic clinical trials has quadrupled in the same time period. This application demonstrates that HCC scientists have made significant contributions to the understanding of cancer biology and the development of novel approaches to prevent, diagnose and treat cancer.